TY  - JOUR
T1  - A Randomized Clinical Trial on Topical Ketorolac Administration Following Phaco-Surgery for Pseudoexfoliation Syndrome
A1  - Mitra Akbari
A1  - Reza Soltani Moghadam
A1  - Anvar Mohamadpour
A1  - Ehsan Kazemnezhad Leili
A1  - Ebrahim Azaripour
JF  - Archives of Pharmacy Practice
JO  - Arch Pharm Pract
SN  - 2320-5210
Y1  - 2024
VL  - 15
IS  - 1
DO  - 10.51847/cvqPvgruf5
SP  - 40
EP  - 46
N2  - The current randomized clinical trial was conducted to determine the influence of topical ketorolac combination with steroids on anterior segment inflammation and other adverse effects following phaco-surgery for pseudoexfoliation (PEX) syndrome. A total of eighty-eight patients with PEX and cataracts who had undergone phacoemulsification participated in the trial. They were randomly placed into one of two groups, which received betamethasone (0.1%) and chloramphenicol (5%) for two weeks, either with or without ketorolac eye drops (0.5%). The two groups' six-month post-operative differences in ACO (Anterior Capsule Opacification) and PCO (Posterior Capsule Opacification) were compared using SPSS 21 software. Measurements of BCVA (Best-Corrected Visual Acuity), IOP (Intraocular Pressure), and ACI (Anterior Chamber Inflammation) were taken on days 1, 3, 7, and 30 after surgery. 

Between the 46 patients in the study group (who took ketorolac) and the 42 patients in the control group (who did not take ketorolac), there was no change in IOP or BCVA on days 30, 7, 3, and 1 following surgery (P > 0.05). The study group had reduced levels of PCO and ACO at six months postoperatively (P 
UR  - https://archivepp.com/article/a-randomized-clinical-trial-on-topical-ketorolac-administration-following-phaco-surgery-for-pseudoex-lgcgnc3ftvutudd
ER  -